CN104185627B - 吡啶酮衍生物 - Google Patents

吡啶酮衍生物 Download PDF

Info

Publication number
CN104185627B
CN104185627B CN201380017353.6A CN201380017353A CN104185627B CN 104185627 B CN104185627 B CN 104185627B CN 201380017353 A CN201380017353 A CN 201380017353A CN 104185627 B CN104185627 B CN 104185627B
Authority
CN
China
Prior art keywords
compound
group
oxo
dihydropyridine
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380017353.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104185627A (zh
Inventor
大木仁
太田雅浩
竹内孝辅
渡边秀昭
山口晓丈
柴田宪宏
富永裕
富永裕一
神保猛
小林庆二朗
小林克弘
深津大辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN104185627A publication Critical patent/CN104185627A/zh
Application granted granted Critical
Publication of CN104185627B publication Critical patent/CN104185627B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380017353.6A 2012-01-31 2013-01-30 吡啶酮衍生物 Expired - Fee Related CN104185627B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012017971 2012-01-31
JP2012-017971 2012-01-31
US201261746039P 2012-12-26 2012-12-26
US61/746039 2012-12-26
PCT/JP2013/052111 WO2013115280A1 (ja) 2012-01-31 2013-01-30 ピリドン誘導体

Publications (2)

Publication Number Publication Date
CN104185627A CN104185627A (zh) 2014-12-03
CN104185627B true CN104185627B (zh) 2018-01-12

Family

ID=48905312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380017353.6A Expired - Fee Related CN104185627B (zh) 2012-01-31 2013-01-30 吡啶酮衍生物

Country Status (30)

Country Link
US (1) US8933103B2 (cg-RX-API-DMAC7.html)
EP (1) EP2810937B1 (cg-RX-API-DMAC7.html)
JP (1) JP6006241B2 (cg-RX-API-DMAC7.html)
KR (1) KR102078530B1 (cg-RX-API-DMAC7.html)
CN (1) CN104185627B (cg-RX-API-DMAC7.html)
AU (1) AU2013216006B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014018702B1 (cg-RX-API-DMAC7.html)
CA (1) CA2863515C (cg-RX-API-DMAC7.html)
CO (1) CO7071126A2 (cg-RX-API-DMAC7.html)
CY (1) CY1118656T1 (cg-RX-API-DMAC7.html)
DK (1) DK2810937T3 (cg-RX-API-DMAC7.html)
ES (1) ES2617484T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170303T1 (cg-RX-API-DMAC7.html)
HU (1) HUE031624T2 (cg-RX-API-DMAC7.html)
IL (1) IL233863A (cg-RX-API-DMAC7.html)
LT (1) LT2810937T (cg-RX-API-DMAC7.html)
MX (1) MX351812B (cg-RX-API-DMAC7.html)
MY (1) MY165215A (cg-RX-API-DMAC7.html)
NZ (1) NZ627586A (cg-RX-API-DMAC7.html)
PH (1) PH12014501719B1 (cg-RX-API-DMAC7.html)
PL (1) PL2810937T3 (cg-RX-API-DMAC7.html)
PT (1) PT2810937T (cg-RX-API-DMAC7.html)
RS (1) RS55728B1 (cg-RX-API-DMAC7.html)
RU (1) RU2632885C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201404505PA (cg-RX-API-DMAC7.html)
SI (1) SI2810937T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201700065T1 (cg-RX-API-DMAC7.html)
TW (1) TWI537259B (cg-RX-API-DMAC7.html)
WO (1) WO2013115280A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201405486B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
EP3067356B1 (en) * 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
AU2014353006B2 (en) 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
JP6496731B2 (ja) 2013-11-27 2019-04-03 シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation Tamファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TWI723572B (zh) * 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
ES2896079T3 (es) 2016-02-26 2022-02-23 Ono Pharmaceutical Co Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
EP3673907A4 (en) 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
TW201940165A (zh) * 2018-01-29 2019-10-16 美商卡普勒斯療法有限責任公司 包含6員中心環的srebp抑制劑
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
TWI840378B (zh) * 2018-07-04 2024-05-01 日商第一三共股份有限公司 二芳基吡啶衍生物之製造方法
PT3842425T (pt) * 2018-08-24 2024-07-02 Transthera Sciences Nanjing Inc Novo inibidor derivado de quinolina
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
AU2020391425A1 (en) * 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN114716370A (zh) * 2021-01-07 2022-07-08 上海翰森生物医药科技有限公司 含吡啶多环类衍生物抑制剂、其制备方法和应用
WO2022220227A1 (ja) * 2021-04-14 2022-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロピリドピリミジン化合物
WO2026014445A1 (ja) * 2024-07-09 2026-01-15 住友化学株式会社 ピリダジン誘導体及びそれを含有する組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070726A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
WO2009047514A1 (en) * 2007-10-10 2009-04-16 Cancer Research Technology Limited [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
WO2009054864A1 (en) * 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CN101796048A (zh) * 2007-07-09 2010-08-04 阿斯利康(瑞典)有限公司 用于治疗增殖病症的三取代的嘧啶衍生物
WO2010126914A1 (en) * 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
CN101910158A (zh) * 2007-10-25 2010-12-08 阿斯利康(瑞典)有限公司 可用于治疗细胞增殖性病症的吡啶衍生物和吡嗪衍生物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2263109C2 (ru) * 1999-05-07 2005-10-27 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО
AU2003223172A1 (en) 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
CA2621503C (en) 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
WO2007057399A2 (en) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
DE602006018354D1 (de) 2005-12-05 2010-12-30 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
US8097630B2 (en) 2006-10-10 2012-01-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
ES2406930T3 (es) 2006-12-29 2013-06-10 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL
RS53281B (sr) 2006-12-29 2014-08-29 Rigel Pharmaceuticals Inc. Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
CA2710051C (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
CN101622248B (zh) 2006-12-29 2013-04-17 里格尔制药公司 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑
CA2710230C (en) 2006-12-29 2016-02-23 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
AU2008240188A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
RU2010120536A (ru) * 2007-10-25 2011-11-27 Астразенека Аб (Se) Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств
WO2009058801A1 (en) 2007-11-02 2009-05-07 Janssen Pharmaceutica, N.V. Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer
ES2531396T3 (es) 2008-01-23 2015-03-13 Bristol Myers Squibb Co Proceso para preparar compuestos de piridinona
EA017736B1 (ru) 2008-01-23 2013-02-28 Бристол-Маерс Сквибб Компани Соединения 4-пиридинона и их применение для лечения рака
JP5746015B2 (ja) 2008-04-16 2015-07-08 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー Axlキナーゼ阻害剤としてのキノリン誘導体
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009138799A1 (en) 2008-05-14 2009-11-19 Astex Therapeutics Limited Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea
CA2730251C (en) 2008-07-09 2016-08-09 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2730231C (en) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
SG172857A1 (en) 2009-02-09 2011-08-29 Supergen Inc Pyrrolopyrimidinyl axl kinase inhibitors
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
JP5970003B2 (ja) 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド アミノピラジン化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070726A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
CN101796048A (zh) * 2007-07-09 2010-08-04 阿斯利康(瑞典)有限公司 用于治疗增殖病症的三取代的嘧啶衍生物
WO2009047514A1 (en) * 2007-10-10 2009-04-16 Cancer Research Technology Limited [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
CN101910158A (zh) * 2007-10-25 2010-12-08 阿斯利康(瑞典)有限公司 可用于治疗细胞增殖性病症的吡啶衍生物和吡嗪衍生物
WO2009054864A1 (en) * 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2010126914A1 (en) * 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins

Also Published As

Publication number Publication date
US20130281428A1 (en) 2013-10-24
SG11201404505PA (en) 2014-10-30
MX2014009246A (es) 2014-10-14
IL233863A (en) 2017-08-31
CN104185627A (zh) 2014-12-03
WO2013115280A1 (ja) 2013-08-08
LT2810937T (lt) 2017-02-10
TWI537259B (zh) 2016-06-11
RU2014135401A (ru) 2016-03-20
HRP20170303T1 (hr) 2017-04-21
ES2617484T3 (es) 2017-06-19
PT2810937T (pt) 2017-03-03
EP2810937A1 (en) 2014-12-10
PH12014501719A1 (en) 2014-11-10
KR20140117439A (ko) 2014-10-07
BR112014018702B1 (pt) 2021-12-14
RS55728B1 (sr) 2017-07-31
CA2863515C (en) 2018-02-27
PL2810937T3 (pl) 2017-07-31
ZA201405486B (en) 2015-11-25
MX351812B (es) 2017-10-27
JP6006241B2 (ja) 2016-10-12
JPWO2013115280A1 (ja) 2015-05-11
NZ627586A (en) 2016-08-26
DK2810937T3 (en) 2017-03-13
SMT201700065T1 (it) 2017-03-08
EP2810937A4 (en) 2015-07-22
SMT201700065B (it) 2017-03-08
CY1118656T1 (el) 2017-07-12
AU2013216006A1 (en) 2014-08-28
KR102078530B1 (ko) 2020-02-18
IL233863A0 (en) 2014-09-30
HK1203504A1 (en) 2015-10-30
MY165215A (en) 2018-03-09
TW201335148A (zh) 2013-09-01
BR112014018702A8 (pt) 2017-07-11
AU2013216006B2 (en) 2017-06-08
US8933103B2 (en) 2015-01-13
BR112014018702A2 (cg-RX-API-DMAC7.html) 2017-06-20
EP2810937B1 (en) 2016-11-30
SI2810937T1 (sl) 2017-01-31
HUE031624T2 (en) 2017-07-28
CA2863515A1 (en) 2013-08-08
PH12014501719B1 (en) 2019-07-17
RU2632885C2 (ru) 2017-10-11
CO7071126A2 (es) 2014-09-30

Similar Documents

Publication Publication Date Title
CN104185627A (zh) 吡啶酮衍生物
JP6203439B2 (ja) テトラヒドロピラニルメチル基を有するピリドン誘導体
JP2016516826A (ja) 重水素化ジアミノピリミジン化合物およびこの化合物を含む薬物組成物
WO2013162061A1 (ja) 二環性ピリミジン化合物
HUE033177T2 (en) Pyrazine carboxamide compound
WO2022246459A9 (en) Combination therapy
CN104926788B (zh) 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN114901655A (zh) 1-噻唑-2-基-吡唑-5-甲酸衍生物的结晶多晶型物
HK1203504B (en) Pyridone derivative
HK40058077A (en) Pyridone derivative having tetrahydropyranylmethyl group
BR112017000242B1 (pt) Composto, cristal, inibidor de axl, medicamento, composição farmacêutica, e, uso de um composto
JP2010018601A (ja) 複素環化合物、その製造法および用途
WO2011059388A1 (en) Oxazolo[4,5-c]pyridine substituted pyrazine
WO2017114863A1 (en) 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
HK1238630B (en) Pyridone derivative having tetrahydropyranyl methyl group
HK1238630A1 (en) Pyridone derivative having tetrahydropyranyl methyl group
JP2010031001A (ja) 複素環化合物、その製造法および用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180112